Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 4Active not recruiting 3Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 3Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 130Lenalidomide 82daratumumab 60Bortezomib 56carfilzomib 45Calcium Dobesilate 41pomalidomide 37Cyclophosphamide 31isatuximab 26belantamab mafodotin 23Specimen Handling 21Biopsy 21Magnetic Resonance Spectroscopy 18dexamethasone acetate 16dexamethasone 21-phosphate 16ixazomib 15auricularum 15fludarabine 13Melphalan 13iberdomide 11elotuzumab 11selinexor 10fludarabine phosphate 9X-Rays 8talquetamab 7venetoclax 6trametinib 6nirogacestat 6Whole-Body Irradiation 6Thalidomide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Diphenhydramine × Plasma cell × Clear all
NCT04268498 2026-03-24

ADVANCE

University of Miami

Phase 2 Active not recruiting
310 enrolled
Plasma cell

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡